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ABSTRACT
Objective: Coronary slow flow phenomenon has been arbitrarily defined as delayed coronary blood flow in the absence of obstructive coronary 
artery disease. The present study sought to investigate the clinical features, natural history, and outcomes of affected patients.
Methods: In this prospective cross-sectional study, 217 consecutive patients who had undergone coronary angiography and showed features 
of coronary slow flow phenomenon were evaluated for demographic and coronary risk factor profile, as well as clinical outcomes, at baseline 
and following treatment.
Results: The study population consisted of 165 (76%) males and 52 (24%) females. The mean age of patients was 52.6±10 years. Mean ejection 
fraction was 48.2±5.4, 39.3% had diabetes, 43.3% had hypertension, 49.8% was a cigarette smoker, 41.9% had dyslipidemia, and 15% had a 
familial history of cardiac disease. Forty-nine percent was detected to have abnormal hsCRP levels. The most prevalent presenting complaint 
was atypical chest pain. Fifty-four percent of patients had slow blood flow in all three vessels. Thirty-six people had undergone repeat coronary 
angiography in a follow-up period of 5-7 years due to persisting or worsening clinical symptoms, of whom 6 (16.6%) showed significant coronary 
artery stenosis. Eight (22.2%) had mild CAD, and the rest still showed coronary slow flow without significant stenosis. The most common com-
plaint during follow-up and after initiation of medical therapy was nonanginal chest pain.
Conclusion: Patients with coronary slow flow phenomenon are predisposed to atherosclerosis and obstructive coronary artery disease. 
Therefore, this pathology should not be considered as a totally benign condition. Primary and secondary cardiovasculature preventive mea-
sures should be constituted and seem worthwhile in this patient population.
(Anatol J Cardiol 2015; 15: 531-5)
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Introduction
One of the most challenging scenarios in cardiovascular 
medicine is the practical approach to patients presenting with 
sample clinical evidence of obstructive coronary artery disease, 
including retrosternal chest discomfort, multiple coronary artery 
disease risk factors, and abnormal noninvasive tests, in whom 
coronary angiography reveals patent coronary vessels that are 
opacified with a noticeable delay after dye injection, or the so-
called “coronary slow flow phenomenon” (1-3). Although this 
phenomenon has been recognized for many decades, there is 
still no firm or convincible pathophysiologic explanation. Some 
studies have mentioned microvascular or endothelial dysfunc-
tion (4-6), while others consider it a preliminary stage of athero-
sclerosis coronary disease (7, 8). There also still remain multiple 
questions and controversies regarding the point over whether 
this pathology is limited to coronary arteries or is a manifesta-
tion of systemic vascular or endothelial disease (8-10). As the 
pathophysiology and natural history of this disorder are yet 
controversial, there is no anonymous treatment strategy 
(2, 11, 12). Previous observational studies have concluded that 
these patients have a good prognosis (1, 2, 8, 10). But, a compre-
hensive study evaluating the long-term prognosis and effective 
pharmacologic treatment is still lacking.
The present study aimed to evaluate the clinical course of 
slow flow coronary phenomenon and the response to conven-
tional treatment protocols in these patients.
Methods
A cohort of 3287 patients who underwent coronary angiogra-
phy between 2006-2013 in our center and had normal epicardial 
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coronary arteries was assessed in this cross-sectional study. 
We used standard Judkins technique for left heart catheteriza-
tion and standard views using right and left‚ caudal, and cranial 
angulations. Angiograms of patients were reassessed, and TIMI 
frame counts were determined for each coronary artery by two 
interventional cardiologists (MAS and MM) (11). Images were 
acquired at 15 frames/s, and all frames were multiplied by 2. LAD 
frame counts were divided by 1.7 for correction of the longer 
length of this vessel. A frame count above 27 for all vessels (after 
correction for LAD as described above) was considered to be 
slow flow based on accepted previous methods (11). We col-
lected our data on the day of catheterization before the patients 
were discharged. A total of 217 patients fulfilled the criteria for 
slow flow phenomenon in our study.
Those with slow flow coronary arteries and concomitant 
disorders, like valvular heart disease (more than mild), cardio-
myopathy, pulmonary arterial hypertension (pulmonary artery 
systolic pressure above 25 mm Hg in transthoracic echocardiog-
raphy), and coronary ectasia, were excluded from the study.
Demographic data regarding age, sex, and cardiovascular 
risk factors (hypertension, diabetes, dyslipidemia, cigarette 
smoking, and familial history of cardiovascular disease) were 
recorded.
Baseline ECG changes, echocardiographic data, non-invasive 
test results, and hsCRP levels were also collected. Blood sam-
ples for measurements of hsCRP were obtained from does diag-
nose with slow flow on the day of coronary angiography. Patients 
were followed for a mean of 5.5±2 years after the initial angiogra-
phy, during which regular office visits were conducted, and the 
presence, absence, worsening, or alleviation of subjective and 
objective clinical symptoms, hospital admissions, noninvasive 
tests, or repeat coronary angiography data were recorded. 
This study was approved by our Center’s Ethics Committee, 
and all patients signed an informed consent form authorizing the 
use of their information for analysis on the day of catheterization 
after confirmation of slow flow. After patients were transferred 
to the ward, data were collected using a form after explaining 
the study’s purpose and protocol, with reassurance that the 
study would not interfere with their treatment drugs.
Statistical analysis
Continuous variables are expressed as mean±standard. 
Categorical data are presented as percent frequencies. One-
sample Kolmogorov-Smirnov test was used to investigate the 
normal distribution for continuous variables. Comparison of the 
variables before and after the follow-up was performed using 
McNemar test. Data were analyzed using SPSS 15.0 for Windows 
(SPSS Inc, Chicago, Illinois, USA). A p value <0.05 was consid-
ered statistically significant.
Results
The study population consisted of 165 (76%) males and 52 
(24%) females; the mean age of participants was 52.6±10 years.
Seventy (32.3%) patients had diabetes, 94 (43.3%) had hyper-
tension, 91 (41.9%) had dyslipidemia, 108 (49.8%) were smokers, 
and 33 patients had a family history of cardiovascular disease. 
Fifty-six percent had hsCRP levels more than 2 mg/L, and 43.3% 
had hsCRP levels below 2 mg/L. Mean left ventricular ejection 
fraction of the patients was 48.2±5.7%. From 217 patient of our 
study population, 109 patients (50.2%) had undergone noninva-
sive tests, including exercise stress testing (60.5%), stress echo-
cardiography (8.4%), and myocardial perfusion imaging or MPI 
(31.1%) that showed abnormal results (Table 1). All patients had 
undergone a coronary angiography due to presentation with 
acute coronary syndromes, including non-ST elevation myocar-
dial infarction (positive troponin I)/unstable angina (NSTEMI/
UA), typical chest discomfort or atypical chest pain accom-
plished by exertional dyspnea, and, for EKG changes, abnormal 
noninvasive tests, as shown in the Table 2.
The coronary angiography results showed that 118 (54%) 
patients had slow flow coronary phenomenon in all 3 vessels‚ 43 
(20%) had it in 2 vessels, and 56 (25%) patients had this abnor-
mality in a single coronary artery. There was no statistically 
significant difference in the prevalence of traditional cardiovas-
cular risk factors between these three groups (p value=0.4). All 
patients had been started on medical therapy after the initial 
diagnosis of slow flow coronary phenomenon, as shown in 
Table 3. Of the patients mentioned above during a mean follow-
up period of 5.5±2 years, 36 patients had undergone a repeat 
Variables Slow flow (n=217)
Demographics
Age‚ year 52.06±10.5
Male 76%
Comorbidities
HTN (%) 43.3%
DM (%) 32.3%
Dyslipidemia (%) 41.9%
Nicotine use (%) 49.8%
Familial history for CAD (positive) 15.2%
hs-CRP (above 2 mg/L) 56%
LVEF (%) at time of admission 48.2±5.7%
EKG changes (%) 76.03%
ST depression 39.6%
T wave inversion 29.3%
ST depression and T wave inversion  27.1%
LBBB and RBBB 7.3%
Without EKG change 23.9%
LVEF (%) in follow up period 46.6±4.8%
CAD - coronary artery disease; DM - diabetes mellitus; EKG - electrocardiogram; 
HTN - hypertension; LBBB - left bundle branch block; LVEF - left ventricular ejection 
fraction; RBBB - right bundle branch block
Table 1. Demographic and clinical characteristics of subjects with 
slow flow
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coronary angiography (once) because of symptom recurrence 
or alleviation. Non-invasive tests during follow-up (MPI: 21 
patients and stress echocardiography in 8 patients) for 29 
(80.5%) of these patients were abnormal. Catheterization showed 
that 22 patients were still slow flow, 8 patients had developed 
mild coronary artery disease (luminal stenosis <50%), and 6 
patients had developed significant coronary stenosis. Thirteen 
patients were lost to follow-up. Mean echocardiographic sys-
tolic LV function showed no significant changes during follow-
up compared with echocardiographic systolic LV function at the 
time of admission.
During the follow-up period, the most prevalent symptom of 
patients was nonanginal chest pain as compared to atypical 
angina pain at first presentation. Clinical symptoms showed a 
statistically significant improvement after initiation of medical 
therapy (p<0.001).
Discussion
Coronary slow flow phenomenon is a frequent angiographic 
finding with obscure pathophysiology (1-3, 8). Considering the 
existing controversy on the treatment and long-term prognosis 
of these patients in the current literature, the present study 
sought to investigate the natural history of these patients. The 
prevalence of coronary slow flow was 6.6% in our study, which 
we believe, considering the relatively adequate sample size, is a 
reliable result. In a study by Hawkins et al. (11), it was reported 
to be 5.5%, whereas Mangieri et al. (4) and Beltrame et al. (13) 
reported a 7% and 1% prevalence, respectively. Higher preva-
lence appears to be more common in populations that are more 
vulnerable to atherosclerotic disease; therefore, it has been 
hypothesized that coronary slow flow phenomenon is a primary 
stage of atherosclerosis, with microvascular or endothelial dys-
function being implicated, as well (7, 8, 11, 14).
The data on demographic variables are also generally limited 
in the literature. In our study, 76% of the patients were male. Some 
studies have reported male gender as a predictor of coronary 
slow flow phenomenon, while others have found no relation 
between sex and slow flow phenomenon (9). The mean age of our 
patients was 52±10 years, which compares well with previous 
studies that reported these patients to be generally younger than 
those with obstructive coronary arteries (11). In our study, there 
was no statistically significant relationship between traditional 
cardiovascular risk factors and coronary slow flow phenomenon, 
but some studies have observed that these patients are more 
likely to suffer from metabolic disorders, including impaired fast-
ing glucose, high triglyceride, low high-density cholesterol, and 
high HbA1c, perhaps because these abnormalities enhance the 
progression of the main underlying disorder (microvascular or 
endothelial dysfunction) (15, 16). Most of our patients had mild 
systolic dysfunction that seemed to be due to baseline microvas-
cular and endothelial dysfunction compared to those with normal 
epicardial coronary arteries (17, 18).
Also, 56% of the study population had hsCRP levels of more 
than 2 mg/L at baseline; however, we do not have follow-up data 
in this regard. There is still controversy regarding the existence 
of a clear and positive relationship between hsCRP and slow 
coronary flow phenomenon (19, 20). Further research in this 
regard seems worthwhile. 
All patients with noninvasive tests performed before cathe-
terization had abnormal test results that seemed to be related 
with the pathophysiologic process of this disease (i.e., microvas-
cular and endothelial dysfunction). Evidence of perfusion abnor-
mality in noninvasive tests must justify anti-ischemic treatment 
strategies in these patients (8, 13, 21, 22).
There is also considerable controversy regarding presenting 
clinical symptoms before coronary angiography. We found atypi-
cal chest discomfort to be the most common, and non-anginal 
chest pain was the most frequent symptom after the first angiog-
raphy and initiation of medical treatment. Some studies report 
atypical chest pain as the most common (11), whereas others 
found typical chest pain to be the most prevalently reported 
symptom (23). In a study of Beltrame et al. (13), resting chest pain 
that required urgent admission was also mentioned (12).
In our study, patients were followed for mean of 5.5 years 
after initiation of anti-ischemia and anti-anginal medication. 
Fourteen (6.4%) patients were found to have developed different 
degrees of coronary artery stenosis during follow-up‚ and there 
were no significant differences in traditional coronary artery 
disease risk factors between these patients and others. To the 
best of our knowledge, no previous studies have had this length 
of follow-up. However, as the limited number of our patients had 
 Symptoms Symptoms 
 before after 
 treatment treatment 
 (n=217) (n=204) P
Unstable angina (%) 30% 3.4% <0.001
Typical chest pain (%) 25.3% 4.4% <0.001
Atypical chest pain (%) 40.5% 17.1% 0.03
Dyspnea on exertion (%) 5.1% 2.4% 0.04
Non-angina chest pain (%) 0% 43.6% <0.001
Asymptomatic (%) 0% 28.9% <0.001
Table 2. Symptoms before and after treatment
Drugs n (%)
Beta-blocker (%) 74.2%
ACEI (%) 95.5%
Ca. channel blocker (%) 67.3%
Aspirin (%) 94.9%
Clopidogrel (%) 33.6%
Anti-depressant (%) 28.6%
Statins (%) 94.9%
ACEI - angiotensin-converting enzyme
Table 3. Drugs used in patients
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developed coronary artery disease and because atherosclero-
sis is known to have a slowly progressive course (24), we could 
not establish a significant statistical relation between the slow 
coronary flow phenomenon and rate of atherosclerotic progres-
sion; however, these results emphasize the need for further 
evaluation of the fate of atherosclerotic disease in this group 
and that the coronary slow flow phenomenon might not be abso-
lutely benign. The alleviation of symptoms during follow-up 
showed that patients benefit from risk factor modification and 
anti-anginal and anti-ischemic therapy. This is also in accor-
dance with previous studies that reported that these patients 
benefit from antiplatelet therapy (11). Statins and nebivolol, pos-
sibly via improvement of endothelial function and reduction of 
inflammation, and diltiazem have also been reported to be used 
with some success in these patients (25-28).
Study limitations
The aim of our study was to evaluate the course and 
response to treatment in this patient population, considering the 
limited existing clinical data in this regard. We did not choose a 
control group and believe that further comparison between 
those with normal coronary arteries and coronary slow flow 
should be the subject of future studies. However, we compared 
the cardiovascular risk of our patients with the risk calculated 
by the Framingham risk scoring system for age- and risk factor-
matched patients.
Conclusion
Coronary slow flow is not a totally benign phenomenon, and 
affected individuals benefit from and deserve to be offered the 
full spectrum of primary and secondary cardiovascular preven-
tive measures.
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